Sensus Healthcare Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Joe Sardano
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 39.43% |
| CEO tenure | 15yrs |
| CEO ownership | 7.1% |
| Management average tenure | 3.9yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Why Sensus Healthcare, Inc. (NASDAQ:SRTS) Could Be Worth Watching
May 06
Investors Shouldn't Be Too Comfortable With Sensus Healthcare's (NASDAQ:SRTS) Earnings
Mar 13Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 25Revenue Beat: Sensus Healthcare, Inc. Beat Analyst Estimates By 5.6%
Feb 08
SRTS Market Outlook
Sensus Healthcare (NASDAQ: SRTS) operates in the Healthcare sector and is part of the Medical Devices industry. Specifically, it focuses on the development and commercialization of non-invasive SuperfWe Think Sensus Healthcare (NASDAQ:SRTS) Might Have The DNA Of A Multi-Bagger
Dec 18Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 19Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares
Nov 12At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?
Oct 03
Fair Deal Agreement And Global Expansion Set To Revolutionize Revenue And Margins
Strategic shift towards recurring revenue with the Fair Deal Agreement model indicates potential for significant revenue growth from 2025.Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
May 12Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
Apr 16Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 11There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital
Oct 17Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger
Jul 04Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop
Mar 14Do Sensus Healthcare's (NASDAQ:SRTS) Earnings Warrant Your Attention?
Mar 06Sensus Healthcare (NASDAQ:SRTS) Could Become A Multi-Bagger
Oct 11Sensus Healthcare Q2 GAAP EPS, revenue beats
Aug 04Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month
May 21Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts
May 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$2m |
| Dec 31 2024 | US$1m | US$500k | US$7m |
| Sep 30 2024 | n/a | n/a | US$9m |
| Jun 30 2024 | n/a | n/a | US$7m |
| Mar 31 2024 | n/a | n/a | US$5m |
| Dec 31 2023 | US$688k | US$450k | US$485k |
| Sep 30 2023 | n/a | n/a | -US$896k |
| Jun 30 2023 | n/a | n/a | US$2m |
| Mar 31 2023 | n/a | n/a | US$6m |
| Dec 31 2022 | US$754k | US$400k | US$24m |
| Sep 30 2022 | n/a | n/a | US$27m |
| Jun 30 2022 | n/a | n/a | US$25m |
| Mar 31 2022 | n/a | n/a | US$21m |
| Dec 31 2021 | US$628k | US$375k | US$4m |
| Sep 30 2021 | n/a | n/a | -US$181k |
| Jun 30 2021 | n/a | n/a | -US$2m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$510k | US$375k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$467k | US$375k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$3m |
| Jun 30 2019 | n/a | n/a | -US$2m |
| Mar 31 2019 | n/a | n/a | -US$3m |
| Dec 31 2018 | US$538k | US$360k | -US$2m |
Compensation vs Market: Joe's total compensation ($USD1.27M) is above average for companies of similar size in the US market ($USD647.10K).
Compensation vs Earnings: Joe's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Joe Sardano (72 yo)
Mr. Joseph C. Sardano, also known as Joe, serves as Director at BioFlorida Inc since August 2021. He Co-Founded Sensus Healthcare, Inc. in 2010 and has been its Chairman of the Board, Chief Executive Offic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15yrs | US$1.27m | 7.15% $ 5.7m | |
| President | 8.4yrs | US$1.28m | 0.70% $ 563.0k | |
| Chief Financial Officer | 5.4yrs | US$656.05k | 0.24% $ 194.4k | |
| Chief Operating Officer | 2.4yrs | no data | 0.091% $ 73.0k | |
| Chief Technology Officer | less than a year | no data | no data | |
| Vice President of Marketing | 2.4yrs | no data | no data |
Experienced Management: SRTS's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15yrs | US$1.27m | 7.15% $ 5.7m | |
| President | 1.3yrs | US$1.28m | 0.70% $ 563.0k | |
| Independent Director | 8.9yrs | US$235.60k | 0.40% $ 323.0k | |
| Member of Medical Advisory Board | 8.4yrs | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 8.4yrs | no data | no data | |
| Member of Medical Advisory Board | 8.3yrs | no data | no data | |
| Member of the Medical Advisory Board | no data | no data | no data | |
| Independent Director | 9.7yrs | US$235.60k | 0.18% $ 145.8k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 7.6yrs | no data | no data | |
| Independent Director | 4.4yrs | US$235.60k | 0.19% $ 155.5k |
Experienced Board: SRTS's board of directors are considered experienced (8.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/30 16:32 |
| End of Day Share Price | 2025/06/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sensus Healthcare, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |
| Vadim Merkulov | Freedom Broker |